Abstract Tricyclodecan-9-yl-xanthogenate (D609) is known for its antiviral and antitumor properties. D609 actions are widely attributed to inhibiting phosphatidylcholine (PC)-specific phospholipase C (PC-PLC). D609 also inhibits sphingomyelin synthase (SMS). PC-PLC and/or SMS inhibition will affect lipid second messengers 1,2-diacylglycerol (DAG) and/or ceramide. Evidence indicates either PC-PLC and/or SMS inhibition affected the cell cycle and arrested proliferation, and stimulated differentiation in various in vitro and in vivo studies. Xanthogenate compounds are also potent antioxidants and D609 reduced Aß-induced toxicity, attributed to its antioxidant properties. Zn 2? is necessary for PC-PLC enzymatic activity; inhibition by D609 might be attributed to its Zn 2? chelation. D609 has also been proposed to inhibit acidic sphingomyelinase or down-regulate hypoxia inducible factor-1a; however these are down-stream events related to PC-PLC inhibition. Characterization of the mammalian PC-PLC is limited to inhibition of enzymatic activity (frequently measured using Amplex red assay with bacterial PC-PLC as a standard). The mammalian PC-PLC has not been cloned; sequenced and structural information is unavailable. D609 showed promise in cancer studies, reduced atherosclerotic plaques (inhibition of PC-PLC) and cerebral infarction after stroke (PC-PLC or SMS). D609 actions as an antagonist to pro-inflammatory cytokines have been attributed to PC-PLC. The purpose of this review is to comprehensively evaluate the literature and summarize the findings and relevance to cell cycle and CNS pathologies.
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Introduction
Tricyclodecan-9-yl-xanthogenate (D609) (Fig. 1) is known for its antiviral, antitumor properties and its effects are widely attributed to inhibiting phosphatidylcholine (PC)-specific phospholipase C (PC-PLC). However the effects of D609 on sphingomyelin synthase (SMS) activity; antioxidant properties; chelation of Zn 2? , effects on various phospholipase A 2 s and anti-inflammatory effects are not ruled out. The purpose of this mini-review is to evaluate the literature and summarize the various findings and their relevance to cell cycle and central nervous system (CNS) pathologies (Table 1) .
Tricyclodecan-9-yl-Xanthogenate (D609)
Xanthates including D609 were initially described as broad spectrum anti-viral compounds [1] . Subsequent results provided evidence that D609 inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced phospholipase C activity in A431 human epidermal carcinoma cells [2] . D609 was shown to be a competitive inhibitor of bacterial phosphatidylcholine (PC)-specific phospholipase C (PC-PLC) and did not inhibit bacterial phosphatidylinositol (PI)-PLC, bovine pancreatic PLA 2 or phospholipase D from cabbage [3] . D609 exists as enantiomeric pairs of 4 diasteriomers and commercial preparations may have undefined, variable mixtures of these 8 isomers (Amtmann, personnel communication). The isomers have different biological efficiency in anti-viral and PC-PLC inhibition assays. Lumavita (Basel, Switzerland) is currently developing LMV-601, an enantiomeric pure isomer of D609, for anti-viral therapy. LMV-601, a PC-PLC inhibitor, reduced expression of high-risk human Papillomavirus (HPV) types 16, 18, 31, and over time improved pre-cancerous cervical cell abnormalities [4] .
PC-PLC (66 kDa) hydrolyzes PC to generate phosphocholine and 1,2-diacylglycerol (DAG). While bacterial PC-PLC has been purified, mammalian PC-PLC has not been cloned and its sequence has not been determined, imposing a limitation on identifying D609 actions on the mammalian enzyme. Rabbit polyclonal antibodies raised against the Bacillus cereus PC-PLC showed cross reactivity against mammalian PC-PLC [5] . Suppressing PC-PLC by D609 in presence or absence of basic fibroblast growth factor (bFGF) stopped proliferation and induced differentiation in various cell systems [6] [7] [8] [9] . In vascular endothelia cells PC-PLC involvement in apoptosis and senescence has been demonstrated [10] [11] [12] . PC-PLC expression changed in a cell-cycle dependent manner inversely with cell division cycle 20 homolog (CDC20) and Cdc20 overexpression caused PC-PLC degradation mediated by ubiquitinproteasome pathway [13] . PC-PLC inhibition by D609 down-regulated human epidermal growth factor receptor 2 (HER2) over-expression on plasma membrane of breast cancer cells [14] Bacterial PC-PLC is a monomeric enzyme which accommodates three Zn 2? ions in the active site likely to be involved in the binding to the substrate and essential for the enzymatic activity and protein conformational stability 
PC-PLC Activity is Often Measured Using the Amplex Red Assay
The principle of the assay is: PC-PLC hydrolyzes PC to DAG and phosphocholine. Phosphocholine is hydrolyzed to choline by alkaline-phosphatase. Choline is oxidized by choline oxidase to betaine and H 2 O 2 . Amplex red reagent is oxidized stiochiometrically by H 2 O 2 in the presence of horseradish peroxidase to generate the fluorescent product resorufin (Ex 530 and Em 590 nm). Activity is calculated against bacterial PC-PLC. Since the assay is indirect, proper controls need to be included to eliminate other sources of H 2 O 2 to obtain the true PC-PLC activity. The contribution of phospholipase D, which hydrolyzes PC to phosphatidic acid and choline (Fig. 2) , can be accounted for by elimination of alkaline phosphatase from the assay.
Sphingolipid Metabolism
The first and rate-limiting step in de novo biosynthesis of ceramide is catalyzed by serine palmitoyltransferase (SPT). SMS transfers the phosphocholine group from PC to ceramide to form SM and DAG. There are two forms of SMS: SMS1 is located in the Golgi apparatus and SMS2 in the plasma membrane [29] . D609 inhibits both forms of SMS [30] [31] [32] . Many of the studies attributing the effects of D609
to PC-PLC inhibition may also involve SMS inhibition (Fig. 3) [53] while 350 lM had no effect [54] . We have shown previously that D609 inhibited proliferation of cultured neuronal progenitor cells and increased metabolic activity in 264.7 macrophages (MTT assay) [55, 56] . The number of BrdU-positive cells was significantly reduced in comparison to controls, indicating that D609 inhibited proliferation of the neurospheres. This could suggest that D609 beneficial effects could arise from inhibiting proliferating microglia/macrophages that are the primary source for TNF-a and IL-1 and other pro-inflammatory cytokines [57] . A composite scheme representing the various actions of D609 has been presented in Fig. 4 .
Relevance of D609 to Inflammation, Proliferation in Neuroscience Paradigm D609 was initially developed as anti-viral and anti-tumor agent that will affect cell proliferation [3] . In neurodegenerative diseases/disorders and CNS injuries, expression of cell cycle regulating proteins (cyclins, cyclin dependent kinases (Cdk) and their endogenous inhibitors) are altered [58] [59] [60] [61] [62] [63] [64] . In dividing non-neuronal cells such as astrocytes, microglia/macrophages, activation of the cell cycle machinery induces proliferation. However, in post-mitotic neurons, cell cycle entry results in their death [58] [59] [60] [61] [62] [63] [64] . Inhibiting the cell cycle will provide benefit by attenuating neuronal death. Hypothetically D609 may block the cell cycle, attenuating neuronal death and non-neuronal cell proliferation by increasing ceramide levels after CNS injury [34] . The role of microglia/macrophages in CNS pathologies remains controversial [65] [66] [67] [68] [69] [70] as they are the source of pro-inflammatory TNF-a and IL-1a/ß [57] as well as trophic factors such as BDNF [68] and IGF-1 that offer protection. Studies indicate that ablation of proliferating microglia exacerbates ischemic injury in mice after transient cerebral ischemia [67] . However ablation of proliferating microglia resulted in an increase in cells expressing TNF-1a, IL-1ß and IL-6, but the identity of these cells were unknown. This could suggest that D609 may prevent mature neurons from entering the cell cycle at the early reperfusion, however may not interfere with proliferation of microglia/macrophages that are the source of trophic factors and active during repair phase of stroke [34] .
Resolving whether microglia/macrophages are the primary source of pro-inflammatory cytokines [57] or other cell(s) in the absence of activated microglia/macrophages will still provide the pro-inflammatory cytokines is challenge. 
